Children who receive growth hormone treatment to help them grow taller may be at a slightly increased risk of having a stroke as young adults, according to a study published in the August 13, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. The researchers caution against either initiating or stopping growth hormone treatment without first talking with their doctor.
“We believe the tens of thousands of people worldwide who are treated with growth hormones should be informed about this risk,” said corresponding study author Joël Coste, MD, PhD, of Paris Descartes University and AP-HP in Paris, France. “More research is needed to show whether the growth hormone treatment is the cause of this increased risk, but in the meantime parents and doctors should consider this association as they weigh their options for treatment.”
The study looked at children who took growth hormone treatment for short stature or growth hormone deficiency with no known cause. The study involved 6,874 people in France who were treated with recombinant growth hormone (not pituitary-derived growth hormone) and were born before 1990 and started treatment between 1985 and 1996.
Researchers then followed up from 2008 to 2010 with health questionnaires and a review of medical records and checked death certificates for the cause of death for any participants who had died. The average time between the start of treatment and the last follow-up was 17 years. Participants were an average age of 11 when they started the growth hormone treatment and took it for an average of 3.9 years.
During the follow-up period, 11 of the participants had a stroke. Of those, eight people had hemorrhagic strokes, which involve bleeding in or around the brain. The strokes occurred at an average age of 24. Four of the people died as a result of the stroke.
The rate of stroke in this group was then compared to the rate of stroke in two registries that collect information on strokes occurring in Dijon, France, and Oxford, United Kingdom. Those registries showed that the expected number of strokes in the group would have been between three and seven cases, rather than the 11 that occurred, making the people treated with growth hormone between 50 percent more likely and 3.6 times more likely to have a stroke than people of similar ages in the general population. A registry of children with small stature who were not treated with recombinant growth hormone would have been a better comparison group, but such a registry is not available.
The results were stronger when looking at just hemorrhagic stroke, where about two cases would have been expected to occur, rather than the eight that did occur, making people treated with growth hormone three to more than four times more likely to have a stroke than those in the general population.
Because the researchers were not able to collect all possible information on every participant, they used a statistical analysis to account for any stroke cases that were missed. That analysis estimated that an additional five strokes may have been missed in the growth hormone group, and that people taking growth hormone were up to nine times more likely to have a hemorrhagic stroke than those in the general population.
“There has been a long-running debate about the usefulness, ethics and cost of growth hormone treatment, especially for otherwise healthy children,” said Rebecca N. Ichord, MD, of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia and a member of the American Academy of Neurology, who wrote an editorial accompanying the study.
“These new results will likely intensify the debate. Doctors who prescribe growth hormone treatment will need to discuss this association, consider its strengths and weaknesses and weigh it in their recommendations. And people who have taken the therapy or start it should be informed about the signs of stroke, the importance of seeking treatment quickly and prevention strategies.”
Coste noted that people who misuse growth hormone treatment to improve athletic performance or body building results should also learn about these findings.
The study received specific funding from the French Ministry of Health, following funding from the French drug safety agency, the French National Institute of Cancer and Commission of European Communities.
To learn more about stroke, please visit www.aan.com/patients.
The American Academy of Neurology, an association of 28,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy.
For more information about the American Academy of Neurology, visit http://www.aan.com
Rachel L. Seroka | American Academy of Neurology
Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
05.12.2016 | Power and Electrical Engineering
05.12.2016 | Materials Sciences
05.12.2016 | Power and Electrical Engineering